WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000025771) METHOD FOR PREVENTING INCREASED IRIDIAL PIGMENTATION DURING PROSTAGLANDIN TREATMENT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/025771    International Application No.:    PCT/SE1999/001993
Publication Date: 11.05.2000 International Filing Date: 04.11.1999
Chapter 2 Demand Filed:    24.05.2000    
IPC:
A61K 31/00 (2006.01), A61K 31/405 (2006.01)
Applicants: SYNPHORA AB [SE/SE]; Dag Hammarskjölds väg 10A S-751 83 Uppsala (SE) (For All Designated States Except US).
STJERNSCHANTZ, Johan [FI/SE]; (SE) (For US Only).
RESUL, Bahram [SE/SE]; (SE) (For US Only)
Inventors: STJERNSCHANTZ, Johan; (SE).
RESUL, Bahram; (SE)
Agent: HOLMBERG, Martin; Bergenstråhle & Lindvall AB Box 17704 S-118 93 Stockholm (SE)
Priority Data:
9803761-7 04.11.1998 SE
Title (EN) METHOD FOR PREVENTING INCREASED IRIDIAL PIGMENTATION DURING PROSTAGLANDIN TREATMENT
(FR) METHODE EMPECHANT L'ACCROISSEMENT DE LA PIGMENTATION IRIDIENNE PENDANT UN TRAITEMENT A LA PROSTAGLANDINE
Abstract: front page image
(EN)Anti-inflammatory agents are used to prevent iridial pigmentation during prostaglandin treatment and to manufacture pharmaceuticals for this purpose. A method for preventing iridial pigmentation as well as a method for treating glaucoma is based on the concomitant or simultaneous administration of a prostaglandin or prostaglandin analogue and an anti-inflammatory agent. Both non-steroid and steroid anti-inflammatory agents can be employed according to the invention.
(FR)L'invention concerne des agents anti-inflammatoires qu'on utilise pour prévenir la pigmentation iridienne au cours d'un traitement à la prostaglandine, et pour fabriquer des médicaments à cette fin. Une méthode de prévention de la pigmentation iridienne et de traitement du glaucome est fondée sur l'administration concomitante ou simultanée d'une prostaglandine ou son analogue et d'un agent anti-inflammatoire. Selon l'invention, des agents anti-inflammatoires tant stéroïdiens que non stéroïdiens peuvent être employés.
Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)